NCT06733688View on ClinicalTrials.gov

A Study to Evaluate Oral Formulations of Tedizolid Phosphate in Healthy Participants (MK-1986-043)

PHASE1CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

March 23, 2022

Primary Completion Date

April 15, 2022

Study Completion Date

April 15, 2022

Conditions
Healthy
Interventions
DRUG

Tedizolid Phosphate Oral Formulation 1 (Reference)

Oral administration

DRUG

Tedizolid Phosphate Oral Formulation 2 (Test)

Oral administration

Trial Locations (1)

68502

Celerion (Site 0001), Lincoln

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY